002653SZSE

Report on Changes in Shareholding of Directors and Senior Management

Haisco Pharmaceutical Group Co., Ltd.··2 pages

✨ AI Summary

Haes科 Pharmaceutical Group Co., Ltd. reports that its total share capital increased to 1,140,892,480 shares following the issuance of 20,974,510 A-shares. Directors and senior management did not participate in the issuance, and their shareholding numbers remained unchanged, resulting in a dilution of their shareholding ratios.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 002653

Securities Abbreviation: Haes科

Announcement No.: 2026-088

Haes科 Pharmaceutical Group Co., Ltd.

Report on Changes in Shareholding of Directors and Senior Management

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, without false records, misleading statements, or major omissions.

According to the "Approval for the Registration of the Issuance of Shares by Haes科 Pharmaceutical Group Co., Ltd. to Specific Objects" (Regulatory Permit (2026) No. 78) issued by the China Securities Regulatory Commission, Haes科 Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") issued 20,974,510 A-shares to specific objects. The Company's total share capital increased from 1,119,917,970 shares to 1,140,892,480 shares.

The current directors and senior management of the Company did not participate in this issuance. Before and after this issuance, the shareholding numbers of the Company

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.